What challenges are pharmaceutical companies facing when attempting to patent AI-assisted drugs?

What is the current environment relating to patent oppositions at the EPO?

What are the fee changes relating to European registered designs due to come into effect on 1 May 2025?

What challenges are pharmaceutical companies facing when attempting to patent AI-assisted drugs?

What is the current environment relating to patent oppositions at the EPO?

What are the fee changes relating to European registered designs due to come into effect on 1 May 2025?

What challenges are pharmaceutical companies facing when attempting to patent AI-assisted drugs?

What is the current environment relating to patent oppositions at the EPO?

What are the fee changes relating to European registered designs due to come into effect on 1 May 2025?